Advances in the Systemic Treatment of Metastatic Melanoma
Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Rising PSA Level in a 46-Year-Old Man
A 46-year-old man sought consultation for an abnormal prostate-specific antigen (PSA) level of 9 ng/mL and one prior negative biopsy. Five months ago, while traveling, he had presented to an urgent care facility with a 24-hour history of fever, chills, nausea, and vomiting. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

New Targets and New Mechanisms in Lung Cancer
This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Making Good Results Even Better: The Evolving Role of Radiotherapy in Patients With Early Diffuse Large B-Cell Lymphoma
If systemic treatment is effective enough to reliably control not only microscopic but also bulky disease, there will be little role for radiotherapy. And if systemic treatment cannot even reliably control microscopic disease, let alone macroscopic disease, there will be little role for radiotherapy, either. However, there are patients who fall into neither of these categories, and in them radiotherapy may well have a role. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news

Radiotherapy Is NOT Essential to Cure Diffuse Large B-Cell Non-Hodgkin Lymphoma
DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy. (Source: Cancer Network)
Source: Cancer Network - May 15, 2013 Category: Cancer & Oncology Source Type: news